Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL
Metrics: PDF 450 views | Full Text 693 views | ?
Yaya Chu1,*, Aradhana Awasthi1,*, Sanghoon Lee1,2, Dina Edani1, Changhong Yin1, Jessica Hochberg1, Tishi Shah1, Tae-Hoon Chung6, Janet Ayello1, Carmella van de Ven1, Christian Klein7, Dean Lee8 and Mitchell S. Cairo1,2,3,4,5
1 Department of Pediatrics, New York Medical College, Valhalla, NY, USA
2 Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA
3 Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA
4 Department of Medicine, New York Medical College, Valhalla, NY, USA
5 Department of Pathology, New York Medical College, Valhalla, NY, USA
6 Cancer Science Institute of Singapore, National University of Singapore, Singapore
7 Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland
8 Department of Pediatrics, Nationwide Children’s Hospital, Columbus, Ohio, USA
* Co-first authors
|Mitchell S. Cairo,||email:||firstname.lastname@example.org|
Keywords: Obinutuzumab; rituximab; survival; primary mediastinal large B-cell lymphoma; antibody-dependent cellular cytotoxicity
Received: March 06, 2020 Accepted: July 14, 2020 Published: August 11, 2020
Primary mediastinal large B-cell lymphoma (PMBL), a distinct mature B-cell lymphoma, expresses CD20 and has recently been successfully treated with the combination of a type I anti-CD20 monoclonal antibody, rituximab, with multiple combination chemotherapy regimens. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody (mAb), recognizing a unique CD20 extracellular membrane epitope with enhanced antibody dependent cellular cytotoxicity (ADCC) vs rituximab. We hypothesize that obinutuzumab vs rituximab will significantly enhance in-vitro and in-vivo cytotoxicity against PMBL. PMBL cells were treated with equal dose of obinutuzumab and rituximab for 24 hours (1–100 μg/ml). ADCC were performed with ex-vivo expanded natural killer cells at 10:1 E: T ratio. Mice were xenografted with intravenous injections of luciferase expressing Karpas1106P cells and treated every 7 days for 8 weeks. Tumor burden was monitored by IVIS spectrum system. Compared with rituximab, obinutuzumab significantly inhibited PMBL cell proliferation (p = 0.01), promoted apoptosis (p = 0.05) and enhanced ADCC (p = 0.0002) against PMBL. Similarly, in PMBL xenografted NOD scid gamma mice, obinutuzumab significantly enhanced survival than rituximab when treated with equal doses (p = 0.05). Taken together our results suggest that obinutuzumab significantly enhanced natural killer cytotoxicity, reduced PMBL proliferation and prolonged the overall survival in humanized PMBL xenografted NOD scid gamma mice.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.